For instance, researchers are investigating the efficiency and safety of atezolizumab(an anti–PD-L1 antibody) in combination with trastuzumab plus pertuzumab in HER2-positive, early high-risk and locally advanced breast cancer (53). Here, ERBB2 is linked to breast carcinoma.